Skip to main content
Clinical Trials/NCT03180320
NCT03180320
Recruiting
N/A

Effect of an Exercise-based Cardiac Rehabilitation Program 'Baduanjin-eight-silken-movement With Self-efficacy Building' for Patients With Chronic Heart Failure in Guangzhou, China (BESMILE-HF Study)

Guangdong Provincial Hospital of Traditional Chinese Medicine1 site in 1 country150 target enrollmentOctober 22, 2018

Overview

Phase
N/A
Intervention
BESMILE-HF program
Conditions
Not specified
Sponsor
Guangdong Provincial Hospital of Traditional Chinese Medicine
Enrollment
150
Locations
1
Primary Endpoint
Change from baseline MLHFQ at 12 week
Status
Recruiting
Last Updated
11 months ago

Overview

Brief Summary

Chronic heart failure (CHF) is a major and growing public health problem and poses economic burden on the society. There is a need for a safe, equipment-free, low-cost, and easily implemented exercise-based cardiac rehabilitation program for CHF patients in China. Baduanjin exercise, translated as 'eight silken movements', is one of the most common forms of traditional Chinese exercise and it could have value to be integrated into a exercise-based cardiac rehabilitation program for CHF patients, together with education, evaluation and consultancy. Accordingly, the BESMILE-HF program applying the Baduanjin exercise as the central component, has been developed in Guangdong Provincial Hospital of Chinese Medicine which is one of the largest hospitals of Chinese medicine in China. This project is to evaluate the efficacy and acceptability of BESMILE-HF program in patients with CHF in China, and it will be based on a randomized controlled trial and a qualitative study.

Registry
clinicaltrials.gov
Start Date
October 22, 2018
End Date
June 30, 2026
Last Updated
11 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Guangdong Provincial Hospital of Traditional Chinese Medicine
Responsible Party
Principal Investigator
Principal Investigator

Weihui Lu

Professor

Guangdong Provincial Hospital of Traditional Chinese Medicine

Eligibility Criteria

Inclusion Criteria

  • aged 18 years or above
  • diagnosed with chronic heart failure
  • clinically stable as defined as symptoms and signs that have remained generally unchanged for at least 1 month
  • NYHA functional class II or III

Exclusion Criteria

  • patients who have contraindications to cardiopulmonary test
  • patients who have contraindications to exercise training
  • Patients who have serious acute or chronic organic disease or mental disorders
  • history of cardiac surgery, cardiac resynchronization therapy, or intracardiac defibrillation within the previous 3 months;
  • history of cardiac arrest within 1 year;
  • history of peripartum cardiomyopathy, hyperthyroid heart disease, primary pulmonary hypertension;
  • inability to perform a bicycle stress test;
  • severe cognitive dysfunction precluding informed consent or understanding of exercise concepts;
  • current regular Baduanjin or current participation in a conventional cardiac rehabilitation program
  • current participation in another trial.

Arms & Interventions

BESMILE-HF group

Throughout the study period, all participants will receive typical Western medications for chronic heart failure, according to national guidelines. In addition, patients will receive the BESMILE-HF program.

Intervention: BESMILE-HF program

BESMILE-HF group

Throughout the study period, all participants will receive typical Western medications for chronic heart failure, according to national guidelines. In addition, patients will receive the BESMILE-HF program.

Intervention: Usual medications

Control

Patients in the control group will receive only the usual medications, since patients typically do not receive exercise-based cardiac rehabilitation in this kind of setting.

Intervention: Usual medications

Outcomes

Primary Outcomes

Change from baseline MLHFQ at 12 week

Time Frame: Baseline,12 week

Minnesota Living with Heart Failure Questionnaire

Change from baseline peak VO2 (ml/kg/min) at 12 week

Time Frame: Baseline, 12 week

Peak oxygen uptake

Secondary Outcomes

  • 6MWT(Baseline, 4 week, 8 week, 12 week)
  • TGUG(Baseline, 4 week, 8 week, 12 week)
  • GRC(Baseline, 4 week, 8 week, 12 week)
  • LVEF (%)(Baseline, 12 week)
  • Global longitudinal strain 2D (%)(Baseline, 12 week)
  • NT pro-BNP(Baseline, 12 week)
  • SEE-C(Baseline, 4 week, 8 week, 12 week)
  • MLHFQ(Baseline, 4 week, 8 week, 12 week)
  • EQ-5D(Baseline, 4 week, 8 week, 12 week)
  • LVEDD (mm)(Baseline, 12 week)
  • LA (mm)(Baseline, 12 week)
  • E/A ratio(Baseline, 12 week)
  • hsCRP(Baseline, 12 week)
  • Total score of Patient Health Questionnaire-9 (PHQ-9)(Baseline, 4 week, 8 week, 12 week)
  • Total score of General Anxiety Disorder-7 (GAD-7)(Baseline, 4 week, 8 week, 12 week)
  • Number of patients who has a increand 6% PeakVO2(Baseline, 12 week)

Study Sites (1)

Loading locations...

Similar Trials